期刊
FUTURE MEDICINAL CHEMISTRY
卷 9, 期 11, 页码 1227-1242出版社
FUTURE SCI LTD
DOI: 10.4155/fmc-2017-0068
关键词
cancer therapy; LSD1 inhibitors; tranylcypromine
资金
- National Natural Science Foundation of China [81373096]
- Zhengzhou University [32210533]
LSD1 has become an important biologically validated epigenetic target for cancer therapy since its identification in 2004. LSD1 mediates many cellular signaling pathways and is involved in the initiation and development of cancers. Aberrant overexpression of LSD1 has been observed in different types of cancers, and inactivation by small molecules suppresses cancer cell differentiation, proliferation, invasion and migration. To date, a large number of LSD1 inhibitors have been reported, RG6016, GSK-2879552, INCB059872, IMG-7289 and CC-90011 are currently undergoing clinical assessment for the treatment of acute myeloid leukemia, small lung cancer cell, etc. In this review, we briefly highlight recent advances of LSD1 inhibitors mainly covering the literatures from 2015 to 2017 and tentatively propose our perspectives on the design of new LSD1 inhibitors for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据